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The treatment of nonsevere pregnancy hypertension has been controversial. Although prior randomized controlled 
trials identified that antihypertensive therapy (to normalize 
blood pressure [BP]) was associated with a lower incidence 
of severe hypertension, it was not clear that this was harmful 
in and of itself, particularly when coupled with concerns that 
such therapy could impair fetal growth and increase perinatal 
mortality and morbidity.1
The CHIPS trial (Control of Hypertension in Pregnancy 
Study) has provided evidence that antihypertensive treatment 
of nonsevere hypertension in pregnancy is of benefit to the 
mother, without associated perinatal risk. The CHIPS trial 
Abstract—To determine whether clinical outcomes differed by occurrence of severe hypertension in the international CHIPS 
trial (Control of Hypertension in Pregnancy Study), adjusting for the interventions of “less tight” (target diastolic blood 
pressure [dBP] 100 mm Hg) versus “tight” control (target dBP 85 mm Hg). In this post-hoc analysis of CHIPS data from 
987 women with nonsevere nonproteinuric preexisting or gestational hypertension, mixed effects logistic regression 
was used to compare the following outcomes according to occurrence of severe hypertension, adjusting for allocated 
group and the influence of baseline factors: CHIPS primary (perinatal loss or high-level neonatal care for >48 hours) 
and secondary outcomes (serious maternal complications), birth weight <10th percentile, preeclampsia, delivery at <34 
or <37 weeks, platelets <100×109/L, elevated liver enzymes with symptoms, maternal length of stay ≥10 days, and 
maternal readmission before 6 weeks postpartum. Three hundred and thirty-four (34.1%) women in CHIPS developed 
severe hypertension that was associated with all outcomes examined except for maternal readmission (P=0.20): CHIPS 
primary outcome, birth weight <10th percentile, preeclampsia, preterm delivery, elevated liver enzymes (all P<0.001), 
platelets <100×109/L (P=0.006), and prolonged hospital stay (P=0.03). The association between severe hypertension and 
serious maternal complications was seen only in less tight control (P=0.02). Adjustment for preeclampsia (464, 47.3%) 
did not negate the relationship between severe hypertension and the CHIPS primary outcome (P<0.001), birth weight 
<10th percentile (P=0.005), delivery at <37 (P<0.001) or <34 weeks (P<0.001), or elevated liver enzymes with symptoms 
(P=0.02). Severe hypertension is a risk marker for adverse maternal and perinatal outcomes, independent of BP control 
or preeclampsia co-occurrence.
Clinical Trial Registration—URL: http://pre-empt.cfri.ca/. Unique identifier: ISRCTN 71416914. URL: https://www.
clinicaltrials.gov/. Unique identifier: NCT01192412.   
(Hypertension. 2016;68:1153-1159. DOI: 10.1161/HYPERTENSIONAHA.116.07862.) • Online Data Supplement
Key Words: antihypertensive therapy ■ hypertension ■ labetalol ■ methyldopa ■ pregnancy
Received May 17, 2016; first decision June 10, 2016; revision accepted August 12, 2016.
From the Molecular and Clinical Sciences Research Institute, St. George’s, University of London and St. George’s NHS Hospitals Foundation Trust, 
United Kingdom (L.A.M., P.v.D.); Department of Obstetrics and Gynaecology (L.A.M., P.v.D., J.M.) and School of Population and Public Health (J. Singer), 
University of British Columbia, Canada; Centre for Health Evaluation and Outcome Sciences (CHÉOS), Providence Health Care Research Institute, UBC, 
Vancouver, Canada (T.L.); Medicine and Obstetrics and Gynaecology, University of Montreal, Canada (E.R.); Obstetrics and Gynaecology, University 
of Alberta, Canada (S.R.); Pediatrics (E.A., S.K.L., G.K.), Obstetrics and Gynaecology (E.A., K.E.M.), The Centre for Mother, Infant and Child Research, 
Sunnybrook Research Institute (E.A., K.E.M., J. Sanchez), and Medicine (A.G.L.), University of Toronto, Canada; Clinical Epidemiology and Biostatistics 
(A.G.) and Obstetrics and Gynaecology (E.H.), McMaster University, Canada; Obstetrics and Gynaecology, University of Manitoba, Canada (M.H.); Obstetrics 
and Gynaecology, University of Amsterdam, Netherlands (W.G.); Obstetrics and Gynaecology, Derriford Hospital, United Kingdom (R.W.); Obstetrics and 
Gynaecology, University of Nottingham, United Kingdom (J.G.T.); and Obstetrics and Gynaecology, Universite de Sherbrooke, Canada (J.-M.M.).
*A list of all CHIPS Study Group participants is given in Table S1 in the online-only Data Supplement.
The online-only Data Supplement is available with this article at http://hyper.ahajournals.org/lookup/suppl/doi:10.1161/HYPERTENSIONAHA. 
116.07862/-/DC1.
Correspondence to Laura A. Magee, St George’s, University of London, Cranmer Terrace, Room J 0.27, London SW17 ORE, United Kingdom. E-mail 
LMagee@sgul.ac.uk
© 2016 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer. This is an open access article 
under the terms of the Creative Commons Attribution Non-Commercial-NoDervis License, which permits use, distribution, and reproduction in any 
medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
The CHIPS Randomized Controlled Trial (Control  
of Hypertension in Pregnancy Study)
Is Severe Hypertension Just an Elevated Blood Pressure?
Laura A. Magee, Peter von Dadelszen, Joel Singer, Terry Lee, Evelyne Rey, Susan Ross,  
Elizabeth Asztalos, Kellie E. Murphy, Jennifer Menzies, Johanna Sanchez, Amiram Gafni,  
Michael Helewa, Eileen Hutton, Gideon Koren, Shoo K. Lee, Alexander G. Logan,  
Wessel Ganzevoort, Ross Welch, Jim G. Thornton, Jean-Marie Moutquin; for the CHIPS Study Group*
Hypertension is available at http://hyper.ahajournals.org DOI: 10.1161/HYPERTENSIONAHA.116.07862
Clinical Trial: CHIPS
1154  Hypertension  November 2016
randomized women with nonsevere pregnancy hyperten-
sion to a diastolic blood pressure (dBP) target of 100 mm Hg 
(“less tight” control) versus 85 mm Hg (“tight” control) for a 
planned between-group difference in dBP of 5 mm Hg.2 The 
BP achieved was higher in less tight (versus tight) control by 
a mean of 5.8 mm Hg systolic (95% confidence interval, 4.5–
7.0; 138.8±0.5 mm Hg versus 133.1±0.5 mm Hg; P<0.001) 
and 4.6 mm Hg diastolic (95% confidence interval, 3.7–5.4; 
89.9±0.3 mm Hg versus 85.3±0.3 mm Hg; P<0.001). There 
was no impact of less tight (versus tight) control on perinatal 
death or high-level neonatal care for >48 hours (155, 31.4% in 
less tight versus 150, 30.7% in tight) or serious maternal com-
plications (including death; 18, 3.7% versus 10, 2.0%, respec-
tively). However, there was more severe maternal hypertension 
(200, 40.6% versus 134, 27.5%, respectively), despite almost 
half the women using home BP monitoring (231, 46.5% ver-
sus 225, 46.0%, respectively) and attending frequent antena-
tal visits (ie, a median [interquartile range] of 7.0 [4.0, 11.0] 
clinic visits from a mean gestational age at enrollment of 24 
weeks [23.7±6.3 versus 24.2±6.3 weeks, respectively]). The 
distribution of observed systolic BP and dBP values was simi-
lar between allocated groups, and the excess of severe BP val-
ues in less tight control was not restricted to values just above 
the 160/110 mm Hg diagnostic threshold for severe hyperten-
sion. In addition, predictive modeling did not demonstrate that 
women destined to develop subsequent severe hypertension 
could be identified by clinical characteristics at randomiza-
tion, when a BP management strategy was instituted.3
The CHIPS trial has generated controversy over whether 
the increase in severe hypertension associated with less tight 
control merits a recommendation to use tight control because 
there is disagreement about whether the increased frequency 
of severe hypertension with less tight control: (1) is important 
to prevent because it would otherwise translate into an excess 
of adverse maternal outcomes for which CHIPS was under-
powered to detect; (2) represents any risk to the fetus; or (3) 
can be identified easily and treated promptly in the course of 
antenatal care.3 In this secondary analysis of CHIPS data, we 
sought to examine whether the occurrence of severe hyper-
tension was associated with adverse perinatal and maternal 
outcomes, independent of allocated group and the occurrence 
of preeclampsia, one of the recognized pathways to adverse 
outcomes for hypertensive mothers and their babies.
Methods
In brief, CHIPS was an open pragmatic international multicenter trial 
(ISRCTN 71416914, NCT01192412, http://pre-empt.cfri.ca/CHIPS) 
that was approved by the Research Ethics Board at the University 
of British Columbia as the Coordinating Center (H08-00882) and at 
all study sites. Women at 14+0- to 33+6-week gestation with nonpro-
teinuric preexisting or gestational hypertension, office dBP 90 to 105 
mm Hg (or 85–105 mm Hg if on antihypertensives), and a live fetus 
were randomized (centrally and stratified by center and type of hyper-
tension) to less tight (target dBP 100 mm Hg) or tight control (target 
dBP 85 mm Hg). For additional details, see Appendix in the online-
only Data Supplement.
Women could be recruited on an antihypertensive agent other than 
atenolol from ≥14 weeks’ gestation. Post randomization, labetalol 
was the recommended antihypertensive of first choice, but women 
could stay on their existing antihypertensive agent if they wished or 
if labetalol were contraindicated or unavailable. (The only exceptions 
were atenolol, angiotensin-converting enzyme inhibitors, angiotensin 
receptor blockers, or direct renin inhibitors.)
The composite primary outcome was pregnancy loss or high-level 
neonatal care for >48 hours in the first 28 days of life, and the sec-
ondary outcome was maternal death or serious maternal complica-
tions before 6 weeks postpartum. Severe hypertension was defined as 
a systolic BP ≥160 mm Hg or a dBP ≥110 mm Hg, measured twice, 
15 minutes apart. Preeclampsia was defined according to Canadian 
clinical practice guidelines4 broadly as the development of new pro-
teinuria or one/more suggestive maternal symptoms (ie, headache, 
visual disturbances, persistent right upper quadrant or epigastric pain, 
severe nausea or vomiting, chest pain, or dyspnea), signs (ie, severe 
hypertension, eclampsia, placental abruption, or pulmonary edema), 
or abnormal laboratory results (ie, elevated aspartate or alanine ami-
notransferase or lactate dehydrogenase [according to local laboratory 
criteria] with symptoms, platelet count <100×109/L, or serum cre-
atinine >2.26 mg/dL [>200 μmol/L]). Further details can be found 
in Table S2 in the online-only Data Supplement and in the CHIPS 
protocol (www.pre-empt.cfri.ca/CHIPS) and in the main CHIPS 
publication.2
Statistical Analysis
Descriptive analyses were undertaken to describe the relationship 
between the occurrence of severe hypertension and the occurrence 
of preeclampsia.
To compare the effect of less tight (versus tight) control among 
women who developed severe hypertension, as opposed to those 
who did not, and the effect of severe hypertension among women 
in less tight, as opposed to those in tight control, a mixed-effects 
logistic regression model was used with an interaction term between 
severe hypertension and allocation group. An additional model with-
out the interaction term was also considered to assess the overall ef-
fect of severe hypertension. We adjusted for the influence of baseline 
factors as in the main CHIPS analysis (ie, stratification factors [hy-
pertension type and center] and key prognostics factors [antihyper-
tensive therapy at randomization, prior BP ≥160/110 mm Hg in this 
pregnancy, gestational age at randomization, region, in-hospital sta-
tus at enrollment, and systolic BP at randomization]) and any others 
that may have differed between those with and those without severe 
hypertension. The same process was undertaken for preeclampsia, 
given the acceptance that it increases maternal and perinatal risk. A 
P value <0.05 was considered statistically significant for the homo-
geneity of the odds ratios (ORs) between women with and without 
each of severe hypertension or preeclampsia, for each of the fol-
lowing adverse outcomes: primary perinatal outcome, secondary 
maternal outcome, severe hypertension, preeclampsia, delivery at 
<37 or 34 weeks, platelet count <100×109/L, elevated aspartate ami-
notransferase or alanine aminotransferase with symptoms, maternal 
length of stay ≥10 days, or maternal readmission before 6 weeks 
postpartum, as applicable.
We further considered the co-occurrence of severe hypertension 
and preeclampsia. These analyses examined the association with 
adverse outcomes for (1) severe hypertension after adjustment for 
preeclampsia, and (2) preeclampsia after adjustment for severe hy-
pertension. A P value <0.05 was considered statistically significant.
All analyses were repeated using a restrictive definition of pre-
eclampsia (ie, the development of new proteinuria, defined as ≥2+ by 
urinary dipstick, ≥0.3 g/d by 24 hours urine collection, or ≥30 mg/
mmol [0.26 mg/mL] urinary creatinine).
Results
For the 981 women randomized and included in the primary 
CHIPS analyses, severe hypertension (N=334, 33.9%) and 
preeclampsia (N=464, 47.3%) were common (Table S3). Most 
women with severe hypertension had preeclampsia (248/334, 
74.5%). Just over half of women with preeclampsia (248/464, 
53.4%) had severe hypertension. No woman had preeclamp-
sia defined only by severe hypertension; one woman had 
Magee et al  Is Severe Hypertension Just an Elevated Blood Pressure?  1155
preeclampsia defined only by signs, but she had both severe 
hypertension and placental abruption, another diagnostic 
criterion for preeclampsia.4 Four hundred and thirty women 
(43.8%) had neither severe hypertension nor preeclampsia.
Because women with severe hypertension or preeclamp-
sia were different from those without each of these outcomes 
according to baseline characteristics (Table S4), additional 
adjustments were required to the mixed logistic regression. 
In brief, women who developed severe hypertension were 
more likely to have been randomized to less tight control 
(as previously reported), be non-Caucasian, have had prior 
severe hypertension in the index pregnancy, be taking aspi-
rin at enrollment, and be from regions outside of North and 
South America that had low perinatal mortality ratios. Women 
who developed preeclampsia were randomized at a later ges-
tational age, and were more likely to: have gestational (ver-
sus preexisting) hypertension, have experienced prior severe 
hypertension, be in hospital at enrollment, taking folic acid or 
aprenatal vitamin at enrollment, and have been recruited from 
South America or UK/Europe.
The adjusted OR (aOR) for adverse outcomes in less tight 
versus tight control was similar among women with and those 
without each of severe hypertension and preeclampsia, as 
reflected by the P value for the homogeneity of the OR (Table 
S5). As in the main results overall, women in less tight control 
more frequently developed severe hypertension.
Table 1 shows raw adverse outcome event rates, presented 
according to the occurrence of severe hypertension or pre-
eclampsia. The raw outcome rates are representative as the ORs 
changed little after adjustment. Adverse outcomes appeared to 
be more frequent among women who developed (as opposed 
to those who did not) severe hypertension or preeclampsia. Not 
shown in Table 1 is the apparently lower frequency of adverse 
outcomes among the 85 women with severe hypertension 
without preeclampsia: primary perinatal outcome (23, 27.1%), 
birth weight <10th percentile (14, 16.9%), secondary maternal 
outcome (1, 1.2%), delivery at <37 (26, 31.0%) or <34 weeks 
(9, 10.7%), platelets <100×109/L (0), elevated liver enzymes 
with symptoms (0), and maternal length of stay ≥10 days (0); 
readmission before 6 weeks was similar (5, 6.0%). Adverse 
outcomes appeared to be lower still among the 430 women 
with neither severe hypertension nor preeclampsia: primary 
perinatal outcome (76, 17.7%); birth weight <10th percentile 
(55, 12.9%); secondary maternal outcome (6, 1.4%); delivery 
at <37 weeks (67, 15.6%) or <34 weeks (25, 5.8%); low plate-
lets (0); elevated liver enzymes with symptoms (0); and mater-
nal length of stay ≥10 days (2, 0.5%).
Table 2 presents aORs for adverse outcomes according to 
the occurrence of severe hypertension or preeclampsia.
Development of severe hypertension was associated with 
more adverse perinatal and maternal outcomes. With few 
exceptions, this was true for all women, those within either 
less tight or tight control, and all women following adjust-
ment for the co-occurrence of preeclampsia. Severe hyper-
tension was associated with the secondary maternal outcome 
only in less tight (aOR 3.74; P=0.02) but not tight control 
(aOR 0.94; P=0.93), although the interaction was not statis-
tically significant (P=0.13). A similar pattern was seen for 
maternal readmission before 6 weeks postpartum in less 
tight (aOR 2.26; P=0.06) but not in tight control (aOR 0.88; 
P=0.81), although power was limited with only 44 women 
readmitted, and there was no significant interaction (P=0.17).
Similarly, development of preeclampsia was associated 
with more adverse outcomes. With few exceptions, this was 
true overall, within each of less tight and tight control, and 
overall following additional adjustment for the co-occurrence 
of postrandomization severe hypertension. Preeclampsia was 
associated with the secondary maternal outcome in less tight 
(aOR 5.48; P=0.01) but not tight control (aOR 1.64; P=0.46), 
although there was no significant interaction (P=0.19). A pat-
tern of reduced risk was seen in tight (aOR 0.34; P=0.05) but 
not less tight control (aOR 1.16; P=0.73) for maternal read-
mission before 6 weeks postpartum, although the results did 
not reach statistical significance and there was no significant 
interaction (P=0.07).
New proteinuria was common (N=280, 28.5%; Table 
S3) and present in almost half of women with severe hyper-
tension (162/334, 48.5%). All results were similar to those 
obtained using a broad definition of preeclampsia. In brief, 
after adjustment for baseline differences between women 
with and those without new proteinuria (Table S4), adverse 
outcomes in less tight versus tight control were similar 
among women with and those without new proteinuria 
(Table S5). Adverse outcome rates appeared to be more fre-
quent among women who developed (as opposed to those 
who did not) new proteinuria (Table S6), and development of 
new proteinuria was associated with more adverse perinatal 
and maternal outcomes (Table S7).
Discussion
Main Findings
In the CHIPS trial, women randomized to less tight control 
more frequently developed severe hypertension, and predic-
tive modeling was unable to identify which women were des-
tined to do so.2,3 Both severe hypertension and preeclampsia, 
a recognized risk marker for adverse outcome, were com-
mon (33.9% and 47.3%, respectively) and often developed 
in the same woman (25.3%), but neither severe hypertension 
nor preeclampsia fully accounted for all women with one or 
more of the adverse outcomes considered. However, severe 
hypertension was associated with higher rates of each of the 
CHIPS primary perinatal outcome, birth weight <10th per-
centile, preeclampsia, delivery at <34 or 37 weeks, plate-
lets <100×109/L, elevated liver enzymes with symptoms, 
and maternal length of hospital stay ≥10 days. Only among 
women in less tight control was severe hypertension, which 
also developed more frequently in these women, associated 
with serious maternal complications (the CHIPS secondary 
outcome) and, possibly, maternal readmission within 6 weeks 
postpartum. The negative impact of severe hypertension on 
outcomes was evident even after adjusting for the negative 
effect of preeclampsia.
Strengths and Limitations
Strengths of our study include the multicenter, international 
nature of the CHIPS trial that speaks to the generalizability 
of the results. Our outcome definitions were rigorous, and we 
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were able to define and adjust for preeclampsia defined both 
broadly and narrowly, increasing the relevance of the results to 
settings where preeclampsia is variably defined in guidelines 
or by practitioners.
A limitation of our study is that these analyses were post 
hoc, albeit in response to views that severe hypertension was a 
benign development and not an outcome worthy of avoidance. 
Also, comparisons of women with/without severe hyperten-
sion or preeclampsia, as with all nonrandomized comparisons, 
may reflect the impact of unknown sources of bias related to 
ways that clinicians manage women. Finally, CHIPS as with 
all randomized controlled trials was powered to detect a major 
effect of less tight (versus tight) control of nonsevere hyper-
tension and underpowered to look at interactions.
Table 1. Outcome Rates According to the Occurrence of Postrandomization Severe Hypertension or Preeclampsia (N Women, %)
Outcomes All Women
Severe Hypertension Preeclampsia
Yes No Yes No
1 (pregnancy loss or high-level neonatal 
care for >48 h)
305/981 (31.1%) 156/334 (46.7%) 149/647 (23.0%) 205/464 (44.2%) 99/515 (19.2%)
  Less tight 155/493 (31.4%) 89/200 (44.5%) 66/293 (22.5%) 103/241 (42.7%) 51/250 (20.4%)
  Tight 150/488 (30.7%) 67/134 (50.0%) 83/354 (23.4%) 102/223 (45.7%) 48/265 (18.1%)
Birth weight <10th percentile 175/976 (17.9%) 79/331 (23.9%) 96/645 (14.9%) 104/463 (22.5%) 69/511 (13.5%)
  Less tight 79/490 (16.1%) 43/198 (21.7%) 36/292 (12.3%) 50/240 (20.8%) 27/248 (10.9%)
  Tight 96/486 (19.8%) 36/133 (27.1%) 60/353 (17.0%) 54/223 (24.2%) 42/263 (16.0%)
2 (maternal death or serious complications) 28/981 (2.9%) 16/334 (4.8%) 12/647 (1.9%) 21/464 (4.5%) 7/515 (1.4%)
  Less tight 18/493 (3.7%) 13/200 (6.5%) 5/293 (1.7%) 15/241 (6.2%) 3/250 (1.2%)
  Tight 10/488 (2.0%) 3/134 (2.2%) 7/354 (2.0%) 6/223 (2.7%) 4/265 (1.5%)
Severe hypertension* 334/981 (34.1%) … … 248/464 (53.4%) 85/515 (16.5%)
  Less tight 200/493 (40.6%) … … 149/241 (61.8%) 50/250 (20.0%)
  Tight 134/488 (27.5%) … … 99/223 (44.4%) 35/265 (13.2%)
Preeclampsia† 464/979 (47.4%) 248/333 (74.5%) 216/646 (33.4%) … …
  Less tight 241/491 (49.1%) 149/199 (74.9%) 92/292 (31.5%) … …
  Tight 223/488 (45.7%) 99/134 (73.9%) 124/354 (35.0%) … …
Delivery <37 wk 328/981 (33.4%) 178/332 (53.6%) 150/646 (23.2%) 234/463 (50.5%) 93/513 (18.1%)
  Less tight 175/492 (35.6%) 106/199 (53.3%) 69/293 (23.5%) 123/240 (51.3%) 51/250 (20.4%)
  Tight 153/486 (31.5%) 72/133 (54.1%) 81/353 (22.9%) 111/223 (49.8%) 42/263 (16.0%)
Delivery <34 wk 138/981 (14.1%) 89/332 (26.8%) 49/646 (7.6%) 103/463 (22.2%) 34/513 (6.6%)
  Less tight 77/492 (15.7%) 55/199 (27.6%) 22/293 (7.5%) 60/240 (25.0%) 16/250 (6.4%)
  Tight 61/486 (12.6%) 34/133 (25.6%) 27/353 (7.6%) 43/223 (19.3%) 18/263 (6.8%)
Platelet count <100×109/L 29/981 (3.0%) 19/334 (5.7%) 10/647 (1.5%) 29/464 (6.3%) 0/515 (0.0%)
  Less tight 21/493 (4.3%) 15/200 (7.5%) 6/293 (2.0%) 21/241 (8.7%) 0/250 (0.0%)
  Tight 8/488 (1.6%) 4/134 (3.0%) 4/354 (1.1%) 8/223 (3.6%) 0/265 (0.0%)
Elevated AST or ALT with symptoms 30/980 (3.1%) 22/334 (6.6%) 8/646 (1.2%) 30/464 (6.5%) 0/515 (0.0%)
  Less tight 21/492 (4.3%) 16/200 (8.0%) 5/292 (1.7%) 21/241 (8.7%) 0/250 (0.0%)
  Tight 9/488 (1.8%) 6/134 (4.5%) 3/354 (0.8%) 9/223 (4.0%) 0/265 (0.0%)
Maternal length of stay ≥10 days 17/981 (1.7%) 12/334 (3.6%) 5/647 (0.8%) 15/464 (3.2%) 2/515 (0.4%)
  Less tight 12/493 (2.4%) 9/200 (4.5%) 3/293 (1.0%) 11/241 (4.6%) 1/250 (0.4%)
  Tight 5/488 (1.0%) 3/134 (2.2%) 2/354 (0.6%) 4/223 (1.8%) 1/265 (0.4%)
Readmitted before 6 wk postpartum 44/971 (4.5%) 19/328 (5.8%) 25/643 (3.9%) 18/458 (3.9%) 26/511 (5.1%)
  Less tight 24/488 (4.9%) 14/197 (7.1%) 10/291 (3.4%) 13/237 (5.5%) 11/249 (4.4%)
  Tight 20/483 (4.1%) 5/131 (3.8%) 15/352 (4.3%) 5/221 (2.3%) 15/262 (5.7%)
ALT indicates alanine aminotransferase; and AST, aspartate aminotransferase.
*All women had severe hypertension, and so a breakdown by severe hypertension is not relevant.
†All women with preeclampsia (broadly defined or restricted to new proteinuria) had preeclampsia, and so a breakdown by preeclampsia is not relevant.
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Table 2. Odds Ratios for Adverse Perinatal and Maternal 
Outcomes, According to Severe Hypertension, Preeclampsia, 
and Allocated Group
Comparison
Adjusted Analysis*
OR 95% CI P Value
1 (pregnancy loss or high-level neonatal care for >48 h)
  Severe hypertension (all women) 3.04 2.21 4.18 <0.001
   Only women in less tight control 2.95 1.92 4.52 <0.001
   Only women in tight control 3.15 2.00 4.94 <0.001
   All women, adjusted for 
preeclampsia†
2.16 1.53 3.04 <0.001
  Preeclampsia (all women) 3.16 2.33 4.30 <0.001
   Only women in less tight control 2.88 1.88 4.41 <0.001
   Only women in tight control 3.48 2.26 5.36 <0.001
   All women, adjusted for severe 
hypertension‡
2.54 1.83 3.54 <0.001
Birth weight <10th percentile
  Severe hypertension (all women) 2.06 1.44 2.96 <0.001
   Only women in less tight control 2.23 1.34 3.71 0.002
   Only women in tight control 1.92 1.17 3.14 0.01
   All women, adjusted for 
preeclampsia†
1.75 1.19 2.58 0.005
  Preeclampsia (all women) 1.81 1.28 2.55 <0.001
   Only women in less tight control 2.16 1.29 3.61 0.004
   Only women in tight control 1.57 0.99 2.48 0.06
   All women, adjusted for severe 
hypertension‡
1.50 1.03 2.18 0.03
2 (maternal death or serious complications)
  Severe hypertension (all women) 2.24 0.98 5.11 0.06
   Only women in less tight control 3.74 1.25 11.22 0.02
   Only women in tight control 0.94 0.22 3.93 0.93
   All women, adjusted for 
preeclampsia†
1.60 0.66 3.87 0.30
  Preeclampsia (all women) 3.28 1.34 8.02 0.01
   Only women in less tight control 5.48 1.53 19.59 0.01
   Only women in tight control 1.64 0.44 6.11 0.46
   All women, adjusted for severe 
hypertension‡
2.70 1.03 7.07 0.04
Severe hypertension
  Preeclampsia (all women) 5.85 4.23 8.08 <0.001
   Only women in less tight control 6.04 3.93 9.30 <0.001
   Only women in tight control 5.62 3.50 9.02 <0.001
    (Adjustment for severe 
hypertension not applicable)
… … … …
Preeclampsia
  Severe hypertension (all women) 6.09 4.37 8.49 <0.001
   Only women in less tight control 7.08 4.55 11.00 <0.001
(Continued )
   Only women in tight control 5.15 3.20 8.28 <0.001
   (Adjustment for preeclampsia 
not applicable)
… … … …
Delivery at <37 wk
  Severe hypertension (all women) 3.99 2.88 5.53 <0.001
   Only women in less tight control 4.13 2.68 6.37 <0.001
   Only women in tight control 3.83 2.41 6.08 <0.001
   All women, adjusted for 
preeclampsia†
2.59 1.83 3.68 <0.001
  Preeclampsia (all women) 4.50 3.27 6.18 <0.001
   Only women in less tight control 4.12 2.66 6.36 <0.001
   Only women in tight control 4.94 3.15 7.74 <0.001
   All women, adjusted for severe 
hypertension‡
3.48 2.48 4.90 <0.001
Delivery at <34 wk
  Severe hypertension (all women) 4.38 2.89 6.65 <0.001
   Only women in less tight control 5.09 2.87 9.02 <0.001
   Only women in tight control 3.72 2.06 6.71 <0.001
   All women, adjusted for 
preeclampsia†
3.07 1.97 4.80 <0.001
  Preeclampsia (all women) 3.73 2.42 5.73 <0.001
   Only women in less tight control 4.66 2.53 8.55 <0.001
   Only women in tight control 2.94 1.60 5.40 <0.001
   All women, adjusted for severe 
hypertension‡
2.61 1.63 4.15 <0.001
Platelet count <100×109/L
  Severe hypertension (all women) 3.20 1.39 7.36 0.006
   Only women in less tight control 3.67 1.33 10.15 0.01
   Only women in tight control 2.46 0.58 10.50 0.22
   All women, adjusted for 
preeclampsia†
1.39 0.65 2.97 0.39
  Preeclampsia (all women) 74.05 5.54 990.2 0.001
   Only women in less tight control 52.59 3.76 735.8 0.003
   Only women in tight control 23.13 1.58 338.7 0.02
   All women, adjusted for severe 
hypertension‡
63.29 4.99 803.5 0.001
Elevated AST or ALT with symptoms
  Severe hypertension (all women) 6.12 2.51 14.91 <0.001
   Only women in less tight control 6.13 2.06 18.26 0.001
   Only women in tight control 6.29 1.47 26.95 0.01
   All women, adjusted for 
preeclampsia†
2.47 1.12 5.43 0.02
  Preeclampsia (all women) 73.32 5.48 981.5 0.001
   Only women in less tight control 50.60 3.61 708.9 0.004
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Interpretation
The CHIPS cohort had a high incidence of adverse outcomes, 
consistent with literature showing a dBP of 90 mm Hg in 
pregnancy identifies a level above which perinatal morbidity 
and other adverse maternal outcomes are increased in non-
proteinuric hypertension.2 Our results are consistent with 
existing randomized controlled trial data that show that less 
tight control is associated with more severe hypertension 
(N=3293 women).5–7 To date, this has been recognized as a 
risk marker for maternal stroke, a rare but devastating (and 
increasing) complication in pregnancy.8,9 Also, our results are 
consistent with a limited literature on the association between 
severe hypertension and adverse outcomes among women 
with chronic hypertension that is severe early in pregnancy5,6 
or after 20 weeks7–9 and among women with severe gesta-
tional hypertension.10,11 However, our study adds to this lit-
erature by demonstrating within the same population that less 
tight control is associated with more severe hypertension, that 
severe hypertension is a risk marker for adverse maternal and 
perinatal outcomes, and that the risks associated with severe 
hypertension are over and above those associated with the co-
occurrence of preeclampsia.
Conclusions
The development of severe hypertension raises concern about 
elevated stroke risk, but the CHIPS data demonstrate that the 
risk of other adverse perinatal and maternal outcomes, includ-
ing serious maternal complications, is also increased, inde-
pendently of the co-occurrence of preeclampsia.
Perspectives
There is more than one pathway that may lead to adverse 
outcomes in hypertensive pregnancy, and women with those 
outcomes may have neither severe hypertension nor pre-
eclampsia, a fact that justifies close antenatal surveillance. 
However, CHIPS data indicate that severe hypertension is 
an outcome worthy of avoidance to minimize maternal and 
perinatal risk. As such, we should move from detection and 
prompt treatment of severe hypertension to prevention. This 
can be achieved with antihypertensive therapy to normalize 
maternal BP, as practiced in the tight BP control arm of the 
CHIPS trial, aiming for a modest dBP of 85 mm Hg. Future 
work should focus on whether one antihypertensive agent 
offers advantages over another.
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   Only women in tight control 24.32 1.67 353.3 0.02
   All women, adjusted for severe 
hypertension‡
54.95 4.28 704.9 0.002
Maternal length of stay ≥10 days
  Severe hypertension (all women) 3.47 1.15 10.44 0.03
   Only women in less tight control 3.64 0.93 14.20 0.06
   Only women in tight control 3.18 0.51 19.92 0.22
   All women, adjusted for 
preeclampsia†
2.01 0.77 5.26 0.15
  Preeclampsia (all women) 6.43 1.93 21.47 0.003
   Only women in less tight control 7.35 1.54 35.04 0.01
   Only women in tight control 3.77 0.69 20.44 0.12
   All women, adjusted for severe 
hypertension‡
4.94 1.45 16.82 0.01
Readmitted before 6 wk postpartum
  Severe hypertension (all women) 1.52 0.80 2.91 0.20
   Only women in less tight  
control
2.26 0.96 5.35 0.06
   Only women in tight control 0.88 0.31 2.52 0.81
   All women, adjusted for 
preeclampsia†
1.91 0.94 3.87 0.07
  Preeclampsia (all women) 0.69 0.37 1.31 0.26
   Only women in less tight  
control
1.16 0.50 2.69 0.73
   Only women in tight control 0.34 0.12 0.98 0.05
   All women, adjusted for severe 
hypertension‡
0.55 0.27 1.10 0.09
ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; 
CHIPS, Control of Hypertension in Pregnancy Study; CI, confidence interval; and 
OR, odds ratio.
*The analyses were adjusted for allocation group, as well as stratification 
factors (ie, type of hypertension, center as a random effect) and baseline 
prognostic factors of prior severe hypertension, antihypertensive therapy at 
randomization (yes/no), gestational diabetes mellitus before randomization, and 
gestational age at randomization (categorical) as in the main CHIPS analysis. We 
further adjusted for any other baseline factors (Table S5) that may have differed 
between those with and those without the outcome (ie, severe hypertension, 
preeclampsia). For platelet count, elevated AST/ALT, and maternal length 
of stay, center was not included as an adjustment variable for the analysis 
involving preeclampsia because of low event rate in the without preeclampsia 
group; Firth bias-correction was used in the logistic regression to account for 
the low event rate.
†The effect of severe hypertension, the effect of treatment allocation (ie, less 
tight or tight control), and the effect of preeclampsia did not vary across groups 
defined by the other 2 variables. As such, in the adjustment, the effect of severe 
hypertension was assumed to be the same in the 2 treatment groups and in 
the 2 preeclampsia groups (ie, women with and women without preeclampsia).
‡The effect of preeclampsia, the effect of treatment allocation (ie, less tight 
or tight control), and the effect of severe hypertension did not vary across 
groups defined by the other 2 variables. As such, in the adjustment, the effect 
of preeclampsia was assumed to be the same in the 2 treatment groups and in 
the 2 severe hypertension groups (ie, women with and women without severe 
hypertension).
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What Is New?
•	Severe hypertension increases the risk of adverse perinatal and maternal 
outcomes beyond stroke.
•	These risks are independent of the risks of preeclampsia.
What Is Relevant?
•	Severe hypertension is not just a bigger blood pressure. Rather, severe 
hypertension is an important clinical outcome worthy of avoidance.
Summary
Women randomized to less tight control in the CHIPS trial (Control 
of Hypertension in Pregnancy Study) more often developed severe 
hypertension, which could not be predicted from clinical charac-
teristics when hypertension developed. Severe hypertension was 
associated with higher rates of the primary perinatal outcome 
(pregnancy loss or high-level neonatal care for >48 hours), birth 
weight <10th percentile, preeclampsia, preterm delivery, platelets 
<100×109/L, elevated liver enzymes with symptoms, and maternal 
length of hospital stay for ≥10 days. Severe hypertension was as-
sociated with the secondary maternal outcomes (maternal death or 
serious maternal complications) only among women in less tight 
control. Severe hypertension remained a significant risk factor for 
adverse maternal and perinatal outcomes even after adjustment 
for preeclampsia.
Novelty and Significance
